Report of Foreign Issuer (6-k)
18 March 2016 - 10:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2016
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 18 March 2016
|
|
|
NOVOGEN LIMITED
(Company) |
|
|
18 March 2016
Mrs Violetta
Codreanu
Adviser, Listings Compliance (Sydney)
ASX
Compliance Pty Ltd
20 Bridge St, Sydney NSW 2000
By
electronic lodgement
Dear Violetta,
Novogen
Limited (ASX:NRT) Results of Meeting
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of
the resolutions and the proxies received in respect of each resolution are set out in the proxy and polls summary attached.
Yours faithfully,
Lionel Mateo
Company
Secretary
NOVOGEN LTD ACN 063 259 754
Level 5, 20 George St, Hornsby, NSW, 2077 | P: +61 (0) 2 9472 4100 - F: +61 (0) 2 9476 0388 | www.novogen.com
Resolution 1 Issue of Options to Dr James Garner
The instructions given to validly appointed proxies in respect of the resolution were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
|
Abstain |
|
|
Open Usable |
|
52,601,296 |
|
|
29,623,298 |
|
|
|
2,008,198 |
|
|
|
2,553,568 |
|
62.05% |
|
|
34.94 |
% |
|
|
|
|
|
|
3.01 |
% |
The motion was carried as an ordinary resolution on a poll the details of which are:
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
|
Abstain |
|
64,595,306 |
|
|
29,623,298 |
|
|
|
4,489,865 |
|
68.56% |
|
|
31.44 |
% |
|
|
|
|
Resolution 2 Election of Mr Iain Ross as a Director
The instructions given to validly appointed proxies in respect of the resolution were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
|
Abstain |
|
|
Open Usable |
|
42,281,237 |
|
|
40,915,280 |
|
|
|
1,185,775 |
|
|
|
2,554,068 |
|
49.30% |
|
|
47.72 |
% |
|
|
|
|
|
|
2.98 |
% |
The motion was carried as an ordinary resolution on a poll the details of which are:
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
|
Abstain |
|
56,321,421 |
|
|
41,269,606 |
|
|
|
1,267,442 |
|
57.71% |
|
|
42.29 |
% |
|
|
|
|
NOVOGEN LTD ACN 063 259 754
Level 5, 20 George St, Hornsby, NSW, 2077 | P: +61 (0) 2 9472 4100 - F: +61 (0) 2 9476 0388 | www.novogen.com
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2024 to May 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From May 2023 to May 2024